Go Pro
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$3.94
-4.8%		$5.26
$2.32
▼
$7.18
$746.94M1.212.49 million shs3.94 million shs
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$14.25
-4.7%		$14.24
$1.54
▼
$18.33
$818.46M0.091.58 million shs1.38 million shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$15.45
+2.6%		$16.09
$7.78
▼
$34.10
$226.78M1.47114,603 shs74,806 shs
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$47.24
-0.1%		$42.74
$24.95
▼
$52.24
$874.03M1.2266,954 shs187,175 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
-4.83%-19.10%-26.08%-16.35%+72.05%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-4.68%-8.18%-0.97%+24.56%+498.74%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+2.59%-3.13%-8.69%-35.79%+35.65%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
-0.08%-2.94%+12.83%+43.81%+29.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$3.94
-4.8%		$5.26
$2.32
▼
$7.18
$746.94M1.212.49 million shs3.94 million shs
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$14.25
-4.7%		$14.24
$1.54
▼
$18.33
$818.46M0.091.58 million shs1.38 million shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$15.45
+2.6%		$16.09
$7.78
▼
$34.10
$226.78M1.47114,603 shs74,806 shs
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$47.24
-0.1%		$42.74
$24.95
▼
$52.24
$874.03M1.2266,954 shs187,175 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
-4.83%-19.10%-26.08%-16.35%+72.05%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-4.68%-8.18%-0.97%+24.56%+498.74%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+2.59%-3.13%-8.69%-35.79%+35.65%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
-0.08%-2.94%+12.83%+43.81%+29.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annexon, Inc. stock logo
ANNX
Annexon
2.40
Hold$15.14284.34% Upside
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3.00
Buy$26.9288.93% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.00
Hold$69.00346.60% Upside
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
2.57
Moderate Buy$59.0024.89% Upside

Current Analyst Ratings Breakdown

Latest GLSI, CLYM, ANNX, and RIGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
9/8/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$18.00 ➝ $25.00
9/8/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$24.00 ➝ $30.00
9/7/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/4/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
B Riley logo
B Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/4/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$26.00 ➝ $30.00
9/3/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOverweight$40.00
9/3/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$21.00 ➝ $25.00
9/3/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$20.00 ➝ $32.00
9/1/2026
Annexon, Inc. stock logo
ANNX
Annexon
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$10.00 ➝ $14.00
8/25/2026
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$1.42 per shareN/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/A$3.36 per shareN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.03 per shareN/A
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$294.28M2.97$6.74 per share7.01$21.57 per share2.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annexon, Inc. stock logo
ANNX
Annexon
-$206.69M-$1.16N/AN/AN/AN/A-106.15%-79.82%11/9/2026 (Estimated)
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$59.85M-$0.83N/AN/AN/AN/A-31.79%-30.79%11/11/2026 (Estimated)
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$19.36M-$1.54N/AN/AN/AN/A-793.81%-295.32%11/13/2026 (Estimated)
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$367.02M$16.322.8910.94N/A116.30%22.95%17.19%11/3/2026 (Estimated)

Latest GLSI, CLYM, ANNX, and RIGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.2388-$0.28-$0.0412-$0.28$6.50 millionN/A
8/11/2026Q2 2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.33-$0.27+$0.06-$0.27N/AN/A
8/6/2026Q2 2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.2093-$0.18+$0.0293-$0.18N/AN/A
8/4/2026Q2 2026
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$0.0877$0.88+$0.7923$0.88$55.28 million$78.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annexon, Inc. stock logo
ANNX
Annexon
N/A
5.53
5.53
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/A
31.45
31.45
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.54
1.54
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
N/A
1.94
1.79

Institutional Ownership

CompanyInstitutional Ownership
Annexon, Inc. stock logo
ANNX
Annexon
N/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
69.76%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
66.23%

Insider Ownership

CompanyInsider Ownership
Annexon, Inc. stock logo
ANNX
Annexon
10.31%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
2.60%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.47%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
10.47%
CompanyEmployeesShares OutstandingFree FloatOptionable
Annexon, Inc. stock logo
ANNX
Annexon
60189.58 million170.03 millionOptionable
Climb Bio, Inc. stock logo
CLYM
Climb Bio
957.44 million55.94 millionN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
314.68 million7.12 millionNot Optionable
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
16018.50 million16.57 millionOptionable

Recent News About These Companies

Rigel Pharmaceuticals (NASDAQ:RIGL) and Aclaris Therapeutics (NASDAQ:ACRS) Critical Contrast
September 11 at 2:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31015956
Bank of New York Mellon Corp Purchases Shares of 108,209 Rigel Pharmaceuticals, Inc. $RIGL
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-purchases-shares-of-108209-rigel-pharmaceuticals-inc-rigl-2026-09-06/
Man Group plc Invests $814,000 in Rigel Pharmaceuticals, Inc. $RIGL
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-man-group-plc-invests-814000-in-rigel-pharmaceuticals-inc-rigl-2026-09-04/
Rigel to Participate in Upcoming September Investor Conferences
September 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/rigel-to-participate-in-upcoming-september-investor-conferences-302866936.html
Jupiter Topco LLC Invests $3.45 Million in Rigel Pharmaceuticals, Inc. $RIGL
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-invests-345-million-in-rigel-pharmaceuticals-inc-rigl-2026-09-02/
Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-takes-position-in-rigel-pharmaceuticals-inc-rigl-2026-09-02/
BlackRock Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-makes-new-investment-in-rigel-pharmaceuticals-inc-rigl-2026-08-31/
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-connor-clark-lunn-investment-management-ltd-buys-shares-of-49096-rigel-pharmaceuticals-inc-rigl-2026-08-30/
Bank of America Corp DE Has $3.90 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGL
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-390-million-stock-holdings-in-rigel-pharmaceuticals-inc-rigl-2026-08-30/
OMERS ADMINISTRATION Corp Invests $2.03 Million in Rigel Pharmaceuticals, Inc. $RIGL
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-omers-administration-corp-invests-203-million-in-rigel-pharmaceuticals-inc-rigl-2026-08-27/
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Moderate Buy" by Brokerages
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-rigel-pharmaceuticals-inc-nasdaq-rigl-given-average-rating-of-moderate-buy-by-brokerages-2026-08-26/
Globeflex Capital L P Takes Position in Rigel Pharmaceuticals, Inc. $RIGL
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-globeflex-capital-l-p-takes-position-in-rigel-pharmaceuticals-inc-rigl-2026-08-24/
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/rigel-pharmaceuticals-nasdaqrigl-rating-increased-to-hold-at-zacks-research-2026-08-19/
HC Wainwright Analysts Increase Earnings Estimates for RIGL
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-analysts-increase-earnings-estimates-for-rigl-2026-08-18/
Rigel Pharmaceuticals
August 17, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/rigl-rigel-pharmaceuticals/vitals
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
August 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/rigel-announces-availability-of-veppanu-vepdegestrant-for-patients-with-erher2--esr1-mutated-advanced-or-metastatic-breast-cancer-302850316.html
Rigel Pharmaceuticals en quête d'acquisitions
August 5, 2026  |  zonebourse.comZ
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931350-rigel-pharmaceuticals-four-drug-stock-with-clinical-catalyst-ahead?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930998-rigel-pharmaceuticals-easy-money-has-been-made-downgrade?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Rigel: Q2 Earnings Snapshot
August 4, 2026  |  aol.comA
Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 4, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930435-rigel-pharmaceuticals-inc-2026-q2-results-earnings-call-presentation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Annexon stock logo

Annexon NASDAQ:ANNX

$3.94 -0.20 (-4.83%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$4.00 +0.06 (+1.50%)
As of 09/11/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Climb Bio stock logo

Climb Bio NASDAQ:CLYM

$14.25 -0.70 (-4.68%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$14.44 +0.19 (+1.30%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$15.45 +0.39 (+2.59%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$15.59 +0.14 (+0.91%)
As of 09/11/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Rigel Pharmaceuticals stock logo

Rigel Pharmaceuticals NASDAQ:RIGL

$47.24 -0.04 (-0.08%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$47.32 +0.07 (+0.16%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas